Accelerator for Cancer Therapeutics
The Accelerator for Cancer Therapeutics (ACT) is a specialized program within TMC Innovation designed to support cancer-focused start-ups and academic founders advancing novel therapeutics. In addition to advisory services related to intellectual property, clinical development, fundraising and commercialization, the program provides access to advanced computational drug discovery capabilities and technical expertise. For Canadian oncology and therapeutics companies considering U.S. expansion, the ACT program offers a practical pathway into the Texas life sciences ecosystem. The ACT program is particularly relevant for Canadian biotech and oncology startups that are progressing from discovery to preclinical development, seeking U.S. market access, or looking to leverage advanced computational drug discovery resources as part of their growth and commercialization strategy.
Who Should Participate
Oncology-focused biotech startups
Drug discovery companies
Academic spinouts developing cancer therapeutics
Companies advancing small-molecule oncology programs
Startups seeking preclinical validation and investor readiness
Canadian companies establishing a subsidiary in Texas
Key Benefits
Strategic guidance on IP, clinical trial design and fundraising
Access to experienced drug discovery and commercialization advisors
Integration of computational and experimental drug development workflows
Support for advancing candidates from hit discovery through lead optimization
Enhanced readiness for partnerships, licensing and investment opportunities
Computational Drug Discovery Capabilities
High-throughput virtual screening and molecular docking
Hit discovery using structure-based and ligand-based approaches
Lead optimization through molecular dynamics and free-energy calculations
Protein-ligand interaction analysis
Cheminformatics and predictive ADMET modeling
Access to high-performance computing infrastructure (CPUs and GPUs)
Access to industry-standard software platforms, including Schrödinger and Cresset
Collaboration with experimental teams for validation and refinement of drug candidates
Join the information session on September 16 at 11:00 am CT.